These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25886603)

  • 41. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
    Dorta P; Kychenthal A
    Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
    Mintz-Hittner HA; Geloneck MM; Chuang AZ
    Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
    Ekinci DY; Çelik K
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.
    Bassiouny RM; Gaafar WM; El Nokrashy A; Abdelhameed AG; Attallah EA; Elgharieb AG; Bassiouny MR
    Eye (Lond); 2022 Nov; 36(11):2137-2143. PubMed ID: 34711941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
    Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
    Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
    Tong Q; Yin H; Zhao M; Li X; Yu W
    BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.
    Salman AG; Said AM
    Ophthalmic Res; 2015; 53(1):15-20. PubMed ID: 25471087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
    Sukgen EA; Koçluk Y
    Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
    Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S
    Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259
    [No Abstract]   [Full Text] [Related]  

  • 54. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
    Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
    Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
    Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
    Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
    Mintz-Hittner HA; Kuffel RR
    Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
    Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience.
    Orozco-Gómez LP; Hernández-Salazar L; Moguel-Ancheita S; Ramírez-Moreno MA; Morales-Cruz MV
    Cir Cir; 2011; 79(3):207-214, 225-32. PubMed ID: 22380989
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
    Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
    Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.